Medicine and Dentistry
Breast Cancer
100%
Malignant Neoplasm
19%
Metastatic Breast Cancer
18%
Adjuvant Chemotherapy
18%
Cyclophosphamide
17%
Symptom
17%
Disease
16%
Doxorubicin
15%
Metastatic Carcinoma
14%
Breast Carcinoma
13%
Hormone Therapy
12%
Recurrent Disease
12%
Hormone Receptor
12%
Neoplasm
12%
Clinical Trial
11%
Patient-Reported Outcome
10%
Overall Survival
10%
Fluorouracil
10%
Gamma Urogastrone
10%
Epidermal Growth Factor Receptor 2
10%
Trastuzumab
9%
High Dose Chemotherapy
9%
Prevalence
9%
Primary Tumor
8%
Dose Densification
8%
Methylation
8%
Biological Marker
8%
Oncologist
8%
Estrogen Receptor
7%
Tamoxifen
7%
Disease Free Survival
7%
Quality of Life
7%
Premenopause
6%
Aromatase Inhibitor
6%
Medical Oncology
6%
Postmenopause
6%
Adjuvant Endocrine Therapy
6%
Oncology
6%
Paclitaxel
5%
Clinical Oncology
5%
Menopausal Symptom
5%
Cardiotoxicity
5%
Drug Megadose
5%
Body Mass Index
5%
Cancer Risk
5%
Chemotherapy Regimens
5%
Arm
5%
Targeted Therapy
5%
Granulocyte Macrophage Colony Stimulating Factor
5%
Cancer Therapy
5%
Keyphrases
Metastatic Breast Cancer
33%
Breast Cancer
28%
Doxorubicin
26%
Cyclophosphamide
23%
Vomiting
23%
Adjuvant Therapy
19%
Anticipatory Nausea
17%
Adjuvant Chemotherapy
15%
Metastasis
14%
Chemotherapy
12%
Nausea
11%
Human Epidermal Growth Factor Receptor 2 (HER2)
10%
Quality of Life
10%
Endocrine Therapy
10%
5-fluorouracil (5-FU)
10%
Chemotherapy Regimen
10%
Early Breast Cancer
9%
Patient-reported Outcomes
9%
Phase II Study
9%
Methotrexate
9%
Cancer Adjuvant
8%
Dose-dense Chemotherapy
8%
Confidence Interval
8%
Women with Breast Cancer
8%
Breast
7%
Primary Tumor
7%
Post-chemotherapy
7%
Adjuvant Endocrine Therapy
7%
Breast Cancer Patients
6%
Working Diagnosis
6%
Overall Survival
6%
Eastern Cooperative Oncology Group
6%
Clonidine
6%
Noradrenergic Activity
6%
Clinical Trials
6%
Operable Breast Cancer
5%
Conventional Chemotherapy
5%
Leucovorin Rescue
5%
Menopausal Symptoms
5%
Postmenopausal Women
5%
Disease-free Survival
5%
Breast Cancer Recurrence
5%
Breast Tumor
5%
Cardiotoxicity
5%
Breast Cancer Treatment
5%
Breast Chemotherapy
5%
Medical Oncologist
5%
Adjuvant Trials
5%
Therapy Discontinuation
5%
Breast Carcinoma
5%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
73%
Chemotherapy
49%
Cyclophosphamide
35%
Doxorubicin
27%
Anticipatory Nausea and Vomiting
26%
Metastatic Breast Cancer
23%
Disease
16%
Fluorouracil
13%
Symptom
12%
Recurrent Disease
12%
Overall Survival
9%
Methotrexate
9%
Chemotherapy Regimens
9%
Disease Free Survival
8%
Hormone Receptor
8%
Vomiting
8%
Polyamine
8%
Neoplasm
8%
Clinical Trial
8%
Pharmacokinetics
7%
Malignant Neoplasm
6%
Receptor
6%
Nausea
6%
Clonidine
6%
Aromatase Inhibitor
6%
High Dose Chemotherapy
5%
Nausea and Vomiting
5%
n1,n11 Diethylnorspermine
5%
Paclitaxel
5%
